Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 11INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Dermatologic 1

Conditions

Neoplasms 2Lymphoma, T-Cell, Peripheral 2Neoplasms by Histologic Type 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × denileukin diftitox × Clear all
NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Eisai Inc.

Phase 2 Completed
75 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

NCT00211185 2020-03-18

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 2 Completed
49 enrolled 11 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01401530 2018-11-23

E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 1 Completed
13 enrolled 18 charts
Lymphoid

Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, T-Cell, Peripheral

NCT00051025 2012-07-13

Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)

Eisai Inc.

Phase 2 Completed
9 enrolled 10 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡